| Report Format: |
PDF |
| Date Published: |
18-Dec-08 |
| Product Type: |
Premium Report |
| Table of
Contents: |
View Table of Contents |
|
|
Introduction
The transplant immunosuppressant market has seen considerable growth in recent years, but this is expected to slow down. Two factors combine to cause a decline in the market from 2011, the limited availability of donor organs and patent expiries of several key products. Neither the shift to once-daily formulations nor the launch of novel biologic therapies will prevent the contraction.
|
Scope
Forecasts for immunosuppressants used in solid organ transplantation and significant pipeline drugs (to 2017 in report and to 2018 in excel tool)Market overview by geographical area, including a rest of the world snapshot and a case study on the Canadian transplant marketFuture market outlook for individual products taking into account key market events, in particular patent expiry and competitor launch datesAn overview of key companies active in the transplant market and their strategies
|
Report
Highlights
Datamonitor expects immunosuppressant sales in the seven major markets to grow to about $4.7 billion annually by 2011, after which the market is forecast to slowly decline to $4.4 billion by 2017 due to key products' patent expiries. The immunosuppressant market overall will be held back by the limited availability of organs.
Bristol-Myers Squibb's once-monthly monoclonal belatacept is expected to be the top-selling single brand in the seven major markets in 2017. However, the combined sales of Astellas's tacrolimus franchise (Prograf and once-daily Advagraf) will dominate the immunosuppressant market over the next ten years.
The toxicity associated with calcineurin inhibitors will lead to more emphasis on immunosuppressive regimens that permit reduction or avoidance of products from this class while maintaining adequate immunosuppression and graft survival. This leads to a fertile environment for novel immunomodulatory approaches.
|
Reasons
to Purchase
Identify key opportunities and threats that will impact the use and uptake of new and existing productsQuantify the future size and scope of the transplant immunosuppressant market and predict the performance of key compoundsUnderstand and capitalize on clinical unmet needs in the market through both lifecycle management of marketed drugs and new product development
|
Table
of Contents
Please click on the link below to view further information on this product (a new window
will open):
View Table of Contents |
